Lion Seizes the Middle Ground
Lion's global SRS licensing deals with Eli Lilly and Johnson & Johnson in January endorse the company's decision to abandon drug discovery and focus on its bioinformatics roots.
You may also be interested in...
PheneX Pharmaceuticals AG is a German biotech start-up formed by a management buy-out of certain drug discovery assets from Lion Bioscience. The firm has embraced a fee-for-service business model, aiming to leverage its expertise in nuclear receptor modulating compounds.
As the financing drought continues and their cash supplies dwindle, biotechs are resorting to big layoffs to drastically cut back on spending (See exhibit 1). But however rigorous a company's turnaround effort, the target of the layoffs always seems to be discovery research, with the remaining employees focusing on clinical programs.
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.